These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1719718)

  • 41. Pseudomonas aeruginosa infection in cystic fibrosis. Relationship between mucoid strains of Pseudomonas aeruginosa and the humoral immune response.
    Hoiby N
    Acta Pathol Microbiol Scand B Microbiol Immunol; 1974 Aug; 82(4):551-8. PubMed ID: 4213330
    [No Abstract]   [Full Text] [Related]  

  • 42. Pseudomonas aeruginosa strains from nosocomial pneumonia are more serum resistant than P. aeruginosa strains from noninfectious respiratory colonization processes.
    Vitkauskiene A; Scheuss S; Sakalauskas R; Dudzevicius V; Sahly H
    Infection; 2005 Oct; 33(5-6):356-61. PubMed ID: 16258867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection.
    Gomi R; Sharma A; Wu W; Sung B; Worgall S
    Vaccine; 2017 Dec; 35(51):7174-7180. PubMed ID: 29126807
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Therapy of established experimental Pseudomonas aeruginosa infections with oral ciprofloxacin and five human monoclonal antibodies against lipopolysaccharide antigens.
    Collins MS; Ladehoff D; Mehton NS
    Antibiot Chemother (1971); 1991; 44():185-95. PubMed ID: 1801636
    [No Abstract]   [Full Text] [Related]  

  • 45. [Pseudomonas aeruginosa and Proteus antigenemia and antibody formation in mono- and mixed infections in patients with suppurative inflammatory diseases].
    Bulava GV; Men'shikov DD; Khvatov VB
    Zh Mikrobiol Epidemiol Immunobiol; 1987 Feb; (2):63-7. PubMed ID: 3107287
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidemiological analysis of serum anti-Pseudomonas aeruginosa PcrV titers in adults.
    Yasumoto H; Katoh H; Kinoshita M; Shimizu M; Hamaoka S; Akiyama K; Naito Y; Sawa T
    Microbiol Immunol; 2016 Feb; 60(2):114-20. PubMed ID: 26696420
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
    Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
    Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Use of hyperimmune anti-Pseudomonas plasma in the treatment of infectious complications].
    Grishina IA; Terekhova RP; Marchuk AI; Elagina LV; Ostrovskaia EV; Nezhlukto AIa
    Khirurgiia (Mosk); 1990 Nov; (11):121-3. PubMed ID: 2127294
    [No Abstract]   [Full Text] [Related]  

  • 49. [Antigenic properties of Pseudomonas aeruginosa anatoxin and the protective action of antitoxic anti-Pseudomonas aeruginosa serum].
    Podgornaia LG; Dziuban NF
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Jun; (6):67-9. PubMed ID: 3092510
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model.
    Imamura Y; Yanagihara K; Fukuda Y; Kaneko Y; Seki M; Izumikawa K; Miyazaki Y; Hirakata Y; Sawa T; Wiener-Kronish JP; Kohno S
    Eur Respir J; 2007 May; 29(5):965-8. PubMed ID: 17301098
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genome-Based Approach Delivers Vaccine Candidates Against
    Bianconi I; Alcalá-Franco B; Scarselli M; Dalsass M; Buccato S; Colaprico A; Marchi S; Masignani V; Bragonzi A
    Front Immunol; 2018; 9():3021. PubMed ID: 30687303
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A human monoclonal antibody cocktail for experimental mouse infection with clinically isolated strains of Pseudomonas aeruginosa].
    Miura S; Ishibashi Y; Arai T
    Kansenshogaku Zasshi; 1993 Dec; 67(12):1167-71. PubMed ID: 8294765
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Common protective antigen (OEP) of Pseudomonas aeruginosa.
    Abe C; Shionoya H; Hirao Y; Okada K; Homma JY
    Jpn J Exp Med; 1975 Oct; 45(5):355-9. PubMed ID: 817054
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Experimental study of the dynamics of the formation of protective antibodies to the antigens of the slime of Pseudomonas aeruginosa].
    Iushkova NA; Stanislavskiĭ ES; Landsman NM
    Zh Mikrobiol Epidemiol Immunobiol; 1983 Mar; (3):78-83. PubMed ID: 6405564
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes in the dependence of Pseudomonas aeruginosa O serogroup strains and their resistance to antibiotics in a university hospital during a 5-year period.
    Vitkauskienė A; Skrodenienė E; Jomantienė D; Macas A; Sakalauskas R
    Medicina (Kaunas); 2011; 47(7):361-7. PubMed ID: 22112984
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunoglobulin allotypes and IgG subclass antibody response to Pseudomonas aeruginosa antigens in chronically infected cystic fibrosis patients.
    Pressler T; Pandey JP; Espersen F; Pedersen SS; Fomsgaard A; Koch C; Høiby N
    Clin Exp Immunol; 1992 Nov; 90(2):209-14. PubMed ID: 1424275
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-PcrV IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models.
    Ranjbar M; Behrouz B; Norouzi F; Mousavi Gargari SL
    Mol Immunol; 2019 Dec; 116():98-105. PubMed ID: 31634816
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunological studies of an artificial antigen with specificity of a common polysaccharide antigen of Pseudomonas aeruginosa.
    Makarenko TA; Kocharova NA; Edvabnaya LS; Tsvetkov YE; Kholodkova EV; Knirel YA; Backinowsky LV; Kochetkov NK; Stanislavsky ES
    FEMS Immunol Med Microbiol; 1993 Oct; 7(3):251-6. PubMed ID: 7506094
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Polish preparations for preventing and treating infections caused by Pseudomonas aeruginosa].
    Schiller B; Buchowicz I; Lysakowska E; Sakiel S; Korbecki M
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Apr; (4):30-2. PubMed ID: 2409720
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.
    Kinoshita M; Kato H; Yasumoto H; Shimizu M; Hamaoka S; Naito Y; Akiyama K; Moriyama K; Sawa T
    Hum Vaccin Immunother; 2016 Nov; 12(11):2833-2846. PubMed ID: 27454613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.